Kane Biotech Inc. announced that on May 24, 2023 it received 510(k) clearance of its coactiv+™? Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations. coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.

It is also indicated for management of minor skin scrapes, minor cuts, minor lacerations, minor burns (1st degree burns) and abrasions for adult populations. coactiv+ Antimicrobial Wound Gel is a white, odorless hydrogel that provides a moist wound environment conducive to wound healing. coactiv+ Antimicrobial Wound Gel can facilitate debridement through a moist wound environment.